tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Cantargia Completes CAN10 Program Sale to Otsuka for Up to $613 Million
Company AnnouncementsCantargia Completes CAN10 Program Sale to Otsuka for Up to $613 Million
1h ago
Cantargia Secures US Patent for Nadunolimab, Boosting Market Position
PremiumCompany Announcements
Cantargia Secures US Patent for Nadunolimab, Boosting Market Position
15d ago
Cantargia AB’s Mid-Year Report Highlights Progress in Antibody-Based Drug Development
PremiumCompany Announcements
Cantargia AB’s Mid-Year Report Highlights Progress in Antibody-Based Drug Development
21d ago
Cantargia AB Appoints Dr. Hilde Steineger as New CEO
PremiumCompany Announcements
Cantargia AB Appoints Dr. Hilde Steineger as New CEO
24d ago
Cantargia AB to Release H1 2025 Interim Report with Investor Presentation
PremiumCompany Announcements
Cantargia AB to Release H1 2025 Interim Report with Investor Presentation
30d ago
Cantargia Reports Preliminary Phase 2 Results for Nadunolimab in TNBC
PremiumCompany AnnouncementsCantargia Reports Preliminary Phase 2 Results for Nadunolimab in TNBC
2M ago
Cantargia’s Nadunolimab Shows Promise in Advanced Lung Cancer Trial
Premium
Company Announcements
Cantargia’s Nadunolimab Shows Promise in Advanced Lung Cancer Trial
2M ago
Cantargia Sells CAN10 Program to Otsuka for $33 Million
Premium
Company Announcements
Cantargia Sells CAN10 Program to Otsuka for $33 Million
2M ago
Cantargia Secures SEK 50 Million Financing to Extend Financial Runway
PremiumCompany Announcements
Cantargia Secures SEK 50 Million Financing to Extend Financial Runway
3M ago
Cantargia’s Nadunolimab Receives FDA Fast Track Designation
PremiumCompany Announcements
Cantargia’s Nadunolimab Receives FDA Fast Track Designation
3M ago
Cantargia’s CAN10 Antibody Shows Promise in Inhibiting Vascular Inflammation
PremiumCompany Announcements
Cantargia’s CAN10 Antibody Shows Promise in Inhibiting Vascular Inflammation
4M ago
Cantargia AB Announces Key Resolutions from Annual General Meeting
PremiumCompany Announcements
Cantargia AB Announces Key Resolutions from Annual General Meeting
4M ago
Cantargia AB’s Promising Interim Report for Early 2025
PremiumCompany AnnouncementsCantargia AB’s Promising Interim Report for Early 2025
4M ago
Cantargia’s CAN10 Achieves Promising Phase 1 Results, Sets Stage for Phase 2
Premium
Company Announcements
Cantargia’s CAN10 Achieves Promising Phase 1 Results, Sets Stage for Phase 2
4M ago
Cantargia’s Nadunolimab Shows Promise in Solid Tumor Treatment
Premium
Company Announcements
Cantargia’s Nadunolimab Shows Promise in Solid Tumor Treatment
4M ago
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immunosuppression
PremiumCompany Announcements
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immunosuppression
5M ago
Cantargia’s Nadunolimab Shows Promise in Overcoming Cancer Immunosuppression
PremiumCompany Announcements
Cantargia’s Nadunolimab Shows Promise in Overcoming Cancer Immunosuppression
5M ago
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immunosuppression
PremiumCompany Announcements
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immunosuppression
5M ago
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immune Suppression
PremiumCompany Announcements
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immune Suppression
5M ago
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immunosuppression
PremiumCompany AnnouncementsCantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immunosuppression
5M ago
Cantargia’s Nadunolimab Shows Promise in Overcoming Cancer Immunosuppression
Premium
Company Announcements
Cantargia’s Nadunolimab Shows Promise in Overcoming Cancer Immunosuppression
5M ago
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immune Suppression
Premium
Company Announcements
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immune Suppression
5M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >